HUDDINGE, Sweden, Jan. 15, 2024 /PRNewswire/ --
XNK's platform, which is used for the manufacturing of evencaleucel, has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. "We are very pleased with EMA's scientific recommendation. This is a necessary step in our regulatory approval journey and will make future interactions easier with the authorities," said Peter Hovstadius Chief Medical Officer at XNK. For more information, please contact:
E-mail: [email protected]
The following files are available for download: